In order to access this content you must be logged in and have a subscription to PL Intelligence.

PL Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.
Fujisawa and Centocor Mutually Agree to Discontinue Co-development of Abciximab in Japan
Fujisawa and SB announce dermatology alliance
Sankyo and Fujisawa Agree to Discontinue Business Arrangements on Sankyo's Antifungal CS-758
Fujisawa Healthcare signs license agreement with Daiichi Suntory
IGI and Fujisawa announce collaboration
TaiGen and Fujisawa sign licensing and collaborative agreement
Aderis announces milestone payment from Fujisawa Healthcare
Tercica Licenses Patent Rights to rhIGF-1 From Fujisawa in Extreme Insulin Resistance